Cerity Partners LLC Sells 2,245 Shares of Insulet Co. (NASDAQ:PODD)

Cerity Partners LLC reduced its stake in Insulet Co. (NASDAQ:PODD - Free Report) by 22.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,948 shares of the medical instruments supplier's stock after selling 2,245 shares during the quarter. Cerity Partners LLC's holdings in Insulet were worth $1,960,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. SBI Securities Co. Ltd. bought a new stake in shares of Insulet in the fourth quarter valued at about $36,000. SRS Capital Advisors Inc. grew its stake in shares of Insulet by 43.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock valued at $49,000 after buying an additional 56 shares in the last quarter. Friedenthal Financial bought a new position in shares of Insulet in the fourth quarter valued at $57,000. Assetmark Inc. increased its holdings in Insulet by 1,447.1% during the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock worth $69,000 after buying an additional 246 shares during the last quarter. Finally, Blue Trust Inc. raised its position in Insulet by 117.3% during the fourth quarter. Blue Trust Inc. now owns 276 shares of the medical instruments supplier's stock worth $72,000 after acquiring an additional 149 shares in the last quarter.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Citigroup boosted their price objective on shares of Insulet from $310.00 to $355.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Piper Sandler upped their price objective on Insulet from $285.00 to $310.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. Canaccord Genuity Group lifted their target price on Insulet from $304.00 to $324.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Wells Fargo & Company boosted their target price on Insulet from $305.00 to $322.00 and gave the stock an "overweight" rating in a report on Friday, February 21st. Finally, Royal Bank of Canada assumed coverage on Insulet in a report on Thursday, March 6th. They set an "outperform" rating and a $340.00 price target for the company. Four investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Insulet has an average rating of "Moderate Buy" and a consensus price target of $292.06.

Insulet Price Performance

Shares of PODD stock traded up $5.45 during trading on Tuesday, hitting $244.02. The company had a trading volume of 550,584 shares, compared to its average volume of 715,908. The firm has a market capitalization of $17.14 billion, a P/E ratio of 42.15, a price-to-earnings-growth ratio of 3.62 and a beta of 1.30. Insulet Co. has a one year low of $160.19 and a one year high of $289.46. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The stock's 50-day moving average price is $261.71 and its 200 day moving average price is $261.16.

Insulet (NASDAQ:PODD - Get Free Report) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating analysts' consensus estimates of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The firm had revenue of $597.50 million during the quarter, compared to the consensus estimate of $582.02 million. Equities analysts expect that Insulet Co. will post 3.92 EPS for the current fiscal year.

Insider Activity

In related news, Director Wayne A.I. Frederick sold 1,825 shares of the firm's stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the sale, the director now directly owns 3,231 shares of the company's stock, valued at $888,525. This trade represents a 36.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.47% of the company's stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.